Published in Clin Colon Rectal Surg on December 01, 2010
Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology (2003) 14.67
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet (2008) 10.47
The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut (2001) 10.07
THE COURSE AND PROGNOSIS OF ULCERATIVE COLITIS. Gut (1963) 6.34
The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol (2007) 6.19
Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med (1994) 6.05
Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology (2005) 5.92
Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol (2010) 5.20
Proctocolectomy without ileostomy for ulcerative colitis. Br Med J (1978) 5.03
Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology (1993) 4.41
Guidelines for the management of inflammatory bowel disease in adults. Gut (2004) 4.15
Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis (2007) 3.83
Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology (1994) 3.81
Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology (2008) 3.79
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology (2009) 3.73
The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology (2001) 3.60
Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol (2002) 3.01
Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol (2005) 2.98
CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS. Gut (1964) 2.97
Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med (1995) 2.95
Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut (2000) 2.86
Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol (2003) 2.86
Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology (2001) 2.81
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis (2001) 2.80
Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med (2003) 2.73
Colon cancer, dysplasia, and surveillance in patients with ulcerative colitis. A critical review. N Engl J Med (1987) 2.61
Surveillance in the routine management of ulcerative colitis: the predictive value of low-grade dysplasia. Gastroenterology (1992) 2.51
Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol (2001) 2.39
Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology (2003) 2.37
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology (2006) 2.34
Infliximab for refractory ulcerative colitis. Am J Gastroenterol (2001) 2.26
Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther (2000) 2.25
Further experience in the treatment of severe attacks of ulcerative colitis. Lancet (1978) 2.25
Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum (2008) 2.05
Estimation of the period prevalence of inflammatory bowel disease among nine health plans using computerized diagnoses and outpatient pharmacy dispensings. Inflamm Bowel Dis (2007) 2.03
Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg (2007) 1.97
Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut (2003) 1.95
Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ (1992) 1.94
The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol (1996) 1.83
Failure of colonoscopic surveillance in ulcerative colitis. Gut (1993) 1.82
Sulphasalazine and male infertility: reversibility and possible mechanism. Gut (1981) 1.80
American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology (2006) 1.78
Oral medication adherence in pediatric inflammatory bowel disease. Inflamm Bowel Dis (2005) 1.75
Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut (2008) 1.75
Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol (2007) 1.72
Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996-2002. Am J Gastroenterol (2008) 1.72
Preoperative colorectal neoplasia increases risk for pouch neoplasia in patients with restorative proctocolectomy. Gastroenterology (2010) 1.72
Outcomes of infants born to mothers with inflammatory bowel disease: a population-based cohort study. Am J Gastroenterol (2002) 1.67
Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology (1994) 1.64
Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology (1996) 1.58
Azathioprine treatment and male fertility in inflammatory bowel disease. Gastroenterology (2001) 1.56
Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med (1998) 1.50
Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev (2007) 1.49
Long-term functional outcome and quality of life after stapled restorative proctocolectomy. Ann Surg (1999) 1.48
Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm Bowel Dis (2007) 1.42
The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol (2007) 1.39
Azathioprine-induced pancreatitis in Crohn's disease: a smoking gun or guilt by association. Aliment Pharmacol Ther (2005) 1.39
Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004. Inflamm Bowel Dis (2007) 1.37
Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut (2008) 1.32
Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol (2006) 1.31
A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol (1997) 1.30
Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis (2010) 1.29
The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol (1990) 1.29
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Can J Gastroenterol (2007) 1.28
MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther (2007) 1.28
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev (2006) 1.25
Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev (2005) 1.22
Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis (2004) 1.22
Nonadherence with thiopurine immunomodulator and mesalamine medications in children with Crohn disease. J Pediatr Gastroenterol Nutr (2007) 1.21
Medication-taking behavior in a cohort of patients with inflammatory bowel disease. Dig Dis Sci (2006) 1.19
Incidence of inflammatory bowel disease in southeastern Norway: evaluation of methods after 1 year of registration. Southeastern Norway IBD Study Group of Gastroenterologists. Digestion (1995) 1.16
Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther (2009) 1.14
Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol (1996) 1.12
Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis (2006) 1.11
MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations. Aliment Pharmacol Ther (2008) 1.10
Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study. Gut (2003) 1.05
The correlation between quality of life and functional outcome in ulcerative colitis patients after proctocolectomy ileal pouch anal anastomosis. Colorectal Dis (2003) 1.02
The risks and the benefits of mesalazine as a treatment for ulcerative colitis. Expert Opin Drug Saf (2007) 1.01
Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis (2001) 1.00
Quality of life of patients with inflammatory bowel disease after surgery. World J Surg (1998) 1.00
Azathioprine, mercaptopurine and birth outcome: a population-based cohort study. Aliment Pharmacol Ther (2003) 0.99
A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin. Inflamm Bowel Dis (1999) 0.96
Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Am J Gastroenterol (2000) 0.96
Colectomy rate in acute severe ulcerative colitis in the infliximab era. Dig Liver Dis (2008) 0.96
A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis. Dig Dis Sci (2008) 0.95
The effects of chronic ill health and treatment with sulphasalazine on fertility amongst men and women with inflammatory bowel disease in Leicestershire. Int J Colorectal Dis (1997) 0.93
Therapeutic strategies for the management of ulcerative colitis. Inflamm Bowel Dis (2009) 0.93
Objective assessment of quality of life following panproctocolectomy and ileostomy for ulcerative colitis. Ann R Coll Surg Engl (2001) 0.92
Fertility, sterility, and pregnancy in chronic inflammatory bowel disease. Scand J Gastroenterol (1982) 0.92
Quality of life after proctocolectomy and ileo-anal anastomosis for severe ulcerative colitis. Am J Gastroenterol (1998) 0.91
Long-term results of low-dose intravenous ciclosporin for acute severe ulcerative colitis. Aliment Pharmacol Ther (2003) 0.91
The role of azathioprine in the management of ulcerative colitis. Dis Colon Rectum (1990) 0.90
Infliximab in severe steroid-refractory ulcerative colitis: a pilot study. Wien Klin Wochenschr (2001) 0.90
A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am J Gastroenterol (2004) 0.90
Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. J Clin Gastroenterol (1997) 0.90
Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study. Gut (1989) 0.89
Infliximab and semen quality in men with inflammatory bowel disease. Inflamm Bowel Dis (2005) 0.89
Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A (2005) 5.05
A consensus document on bowel preparation before colonoscopy: prepared by a task force from the American Society of Colon and Rectal Surgeons (ASCRS), the American Society for Gastrointestinal Endoscopy (ASGE), and the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES). Gastrointest Endosc (2006) 4.31
Paneth cell trypsin is the processing enzyme for human defensin-5. Nat Immunol (2002) 3.13
A phenylalanine in DGAT is a key determinant of oil content and composition in maize. Nat Genet (2008) 2.89
Management of antithrombotic agents for endoscopic procedures. Gastrointest Endosc (2009) 2.84
Sedation and anesthesia in GI endoscopy. Gastrointest Endosc (2008) 2.73
ASGE guideline: colorectal cancer screening and surveillance. Gastrointest Endosc (2006) 2.63
Human α-defensin 6 promotes mucosal innate immunity through self-assembled peptide nanonets. Science (2012) 2.44
Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients. J Gastrointest Surg (2008) 2.29
Therapeutic Armamentarium for Stricturing Crohn's Disease: Medical Versus Endoscopic Versus Surgical Approaches. Inflamm Bowel Dis (2015) 2.13
G protein subunit Galpha13 binds to integrin alphaIIbbeta3 and mediates integrin "outside-in" signaling. Science (2010) 2.09
Antibiotic prophylaxis for GI endoscopy. Gastrointest Endosc (2008) 2.08
Infection control during GI endoscopy. Gastrointest Endosc (2008) 2.07
Twenty-year-old stapled pouches for ulcerative colitis without evidence of rectal cancer: implications for surveillance strategy? Dis Colon Rectum (2014) 2.01
Ileal pouch anal anastomosis: analysis of outcome and quality of life in 3707 patients. Ann Surg (2013) 1.91
Postischemic brain injury is exacerbated in mice lacking the kinin B2 receptor. Hypertension (2006) 1.80
Preoperative colorectal neoplasia increases risk for pouch neoplasia in patients with restorative proctocolectomy. Gastroenterology (2010) 1.72
Esophageal dilation. Gastrointest Endosc (2006) 1.68
Tissue kallikrein promotes neovascularization and improves cardiac function by the Akt-glycogen synthase kinase-3beta pathway. Cardiovasc Res (2008) 1.67
Risk and location of cancer in patients with preoperative colitis-associated dysplasia undergoing proctocolectomy. Ann Surg (2014) 1.58
Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. Gastroenterology (2004) 1.58
Progressive primary sclerosing cholangitis requiring liver transplantation is associated with reduced need for colectomy in patients with ulcerative colitis. Clin Gastroenterol Hepatol (2012) 1.56
The NOD2insC polymorphism is associated with worse outcome following ileal pouch-anal anastomosis for ulcerative colitis. Gut (2012) 1.51
Whole genome scan detects an allelic variant of fad2 associated with increased oleic acid levels in maize. Mol Genet Genomics (2007) 1.50
Paneth cell antimicrobial peptides: topographical distribution and quantification in human gastrointestinal tissues. FEBS Lett (2006) 1.44
Dysplasia associated with Crohn's colitis: segmental colectomy or more extended resection? Ann Surg (2012) 1.43
Endoscopy by nonphysicians. Gastrointest Endosc (2009) 1.42
Preoperative Clostridium difficile infection is not associated with an increased risk for the infection in ileal pouch patients. Dig Dis Sci (2014) 1.39
The presence of primary sclerosing cholangitis is protective for ileal pouch from Crohn's disease. Inflamm Bowel Dis (2013) 1.39
ASGE guideline: endoscopy in the diagnosis and treatment of inflammatory bowel disease. Gastrointest Endosc (2006) 1.36
Mannopeptimycins, novel antibacterial glycopeptides from Streptomyces hygroscopicus, LL-AC98. J Am Chem Soc (2002) 1.33
Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis (2010) 1.29
The role of endoscopy in ampullary and duodenal adenomas. Gastrointest Endosc (2006) 1.28
The role of endoscopy in patients with chronic pancreatitis. Gastrointest Endosc (2006) 1.26
Modifications in endoscopic practice for pediatric patients. Gastrointest Endosc (2008) 1.25
Novel role of kallistatin in protection against myocardial ischemia-reperfusion injury by preventing apoptosis and inflammation. Hum Gene Ther (2006) 1.23
Role of EUS. Gastrointest Endosc (2007) 1.23
Kallikrein-modified mesenchymal stem cell implantation provides enhanced protection against acute ischemic kidney injury by inhibiting apoptosis and inflammation. Hum Gene Ther (2008) 1.20
Tissue kallikrein elicits cardioprotection by direct kinin b2 receptor activation independent of kinin formation. Hypertension (2008) 1.14
Kallistatin inhibits vascular inflammation by antagonizing tumor necrosis factor-alpha-induced nuclear factor kappaB activation. Hypertension (2010) 1.12
Chiral proton catalysis: enantioselective Brønsted acid catalyzed additions of nitroacetic acid derivatives as glycine equivalents. J Am Chem Soc (2007) 1.12
Depletion of endogenous kallistatin exacerbates renal and cardiovascular oxidative stress, inflammation, and organ remodeling. Am J Physiol Renal Physiol (2012) 1.10
Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing. Biol Chem (2010) 1.10
Tissue kallikrein protects against pressure overload-induced cardiac hypertrophy through kinin B2 receptor and glycogen synthase kinase-3beta activation. Cardiovasc Res (2006) 1.09
Secondary pouchitis: those with identifiable etiopathogenetic or triggering factors. Am J Gastroenterol (2009) 1.09
Role of endoscopy in the bariatric surgery patient. Gastrointest Endosc (2008) 1.08
MicroRNA-181a promotes gastric cancer by negatively regulating tumor suppressor KLF6. Tumour Biol (2012) 1.07
Long-term outcomes with ileal pouch-anal anastomosis and Crohn's disease: pouch retention and implications of delayed diagnosis. Ann Surg (2008) 1.07
Clinical guidelines for the management of pouchitis. Inflamm Bowel Dis (2009) 1.06
Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro. Hepatology (2010) 1.05
Reversal of renal fibrosis, inflammation, and glomerular hypertrophy by kallikrein gene delivery. Hum Gene Ther (2006) 1.04
Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease. J Crohns Colitis (2012) 1.04
Racial and socioeconomic disparities in nutrition behaviors: targeted interventions needed. J Nutr Educ Behav (2009) 1.04
YouTube and inflammatory bowel disease. J Crohns Colitis (2012) 1.04
Characteristics of fecal and mucosa-associated microbiota in Chinese patients with inflammatory bowel disease. Medicine (Baltimore) (2014) 1.03
Ileal pouch prolapse: prevalence, management, and outcomes. J Gastrointest Surg (2010) 1.03
The role of endoscopy in the management of patients with known and suspected colonic obstruction and pseudo-obstruction. Gastrointest Endosc (2010) 1.03
ASGE guideline: modifications in endoscopic practice for the elderly. Gastrointest Endosc (2006) 1.03
Sedation and anesthesia in GI endoscopy. Gastrointest Endosc (2008) 1.02
Clostridium difficile infection is associated with worse long term outcome in patients with ulcerative colitis. J Crohns Colitis (2011) 1.00
Role of endoscopy in the management of GERD. Gastrointest Endosc (2007) 1.00
Discovery of competing anaerobic and aerobic pathways in umpolung amide synthesis allows for site-selective amide 18O-labeling. Proc Natl Acad Sci U S A (2011) 0.99
Engineering for drought avoidance: expression of maize NADP-malic enzyme in tobacco results in altered stomatal function. J Exp Bot (2002) 0.99
Enantioselective synthesis of α-oxy amides via Umpolung amide synthesis. J Am Chem Soc (2012) 0.99
Informed consent for GI endoscopy. Gastrointest Endosc (2007) 0.99
Factors associated with ileoanal pouch failure in patients developing early or late pouch-related fistula. Dis Colon Rectum (2011) 0.98
Enhanced anisotropic effective g factors of an Al0.25Ga0.75N/GaN heterostructure based quantum point contact. Nano Lett (2013) 0.98
Endoscopic therapy in inflammatory bowel diseases (with videos). Gastrointest Endosc (2013) 0.98
Pouchitis: lessons for inflammatory bowel disease. Curr Opin Gastroenterol (2009) 0.98
Clostridium difficile infection and inflammatory bowel disease: understanding the evolving relationship. World J Gastroenterol (2010) 0.97
Serological investigation of subclinical influenza A(H7H9) infection among healthcare and non-healthcare workers in Zhejiang Province, China. Clin Infect Dis (2013) 0.97
Pelvic sepsis after IPAA adversely affects function of the pouch and quality of life. Dis Colon Rectum (2012) 0.96
Rattle-structured multifunctional nanotheranostics for synergetic chemo-/radiotherapy and simultaneous magnetic/luminescent dual-mode imaging. J Am Chem Soc (2013) 0.96
Serine proteinase over-expression in relation to deltamethrin resistance in Culex pipiens pallens. Arch Biochem Biophys (2005) 0.95
A new category of autoinflammatory disease associated with NOD2 gene mutations. Arthritis Res Ther (2011) 0.95
New, goal-directed approach to renal replacement therapy improves acute kidney injury treatment after cardiac surgery. J Cardiothorac Surg (2014) 0.95
Diagnosis and management of afferent limb syndrome in patients with ileal pouch-anal anastomosis. Inflamm Bowel Dis (2010) 0.95
Position statement on routine laboratory testing before endoscopic procedures. Gastrointest Endosc (2008) 0.94
Kinin infusion prevents renal inflammation, apoptosis, and fibrosis via inhibition of oxidative stress and mitogen-activated protein kinase activity. Hypertension (2007) 0.93
Differentiating risk factors for acute and chronic pouchitis. Clin Gastroenterol Hepatol (2005) 0.93
The role of endoscopy in the management of patients with diarrhea. Gastrointest Endosc (2010) 0.93
Surgical outcome in patients with primary sclerosing cholangitis undergoing ileal pouch-anal anastomosis: a case-control study. Surgery (2005) 0.93
Increased serum levels of carbohydrate antigen 19-9 and outcomes in primary sclerosing cholangitis patients without cholangiocarcinoma. Dig Dis Sci (2012) 0.92
An examination of the multidimensionality of situational interest in elementary school physical education. Res Q Exerc Sport (2008) 0.92
Health care-associated transmission of hepatitis B and C viruses in endoscopy units. Clin Liver Dis (2010) 0.92
The role of 5'-adenylylsulfate reductase in controlling sulfate reduction in plants. Photosynth Res (2005) 0.92
Management of leak from the tip of the "J" in ileal pouch-anal anastomosis. Dis Colon Rectum (2011) 0.91
Mannopeptimycin esters and carbonates, potent antibiotic agents against drug-resistant bacteria. Bioorg Med Chem Lett (2004) 0.91
Impact of Clostridium difficile infection in patients with ulcerative colitis. J Crohns Colitis (2010) 0.90
Tissue kallikrein and kinin infusion rescues failing myocardium after myocardial infarction. J Card Fail (2007) 0.90
Acute pancreatitis in pregnancy. Acta Obstet Gynecol Scand (2011) 0.90
Endoscopic needle-knife therapy for ileal pouch sinus: a novel approach for the surgical adverse event (with video). Gastrointest Endosc (2013) 0.90
Preoperative pelvic radiation increases the risk for ileal pouch failure in patients with colitis-associated colorectal cancer. J Crohns Colitis (2013) 0.90
Lymphocytic colitis and collagenous colitis: a review of clinicopathologic features and immunologic abnormalities. Adv Anat Pathol (2012) 0.90
MicroRNA expression patterns in indeterminate inflammatory bowel disease. Mod Pathol (2012) 0.90
Clinical course of cuffitis in ulcerative colitis patients with restorative proctocolectomy and ileal pouch-anal anastomoses. Inflamm Bowel Dis (2013) 0.89
Genetic polymorphism at miR-181a binding site contributes to gastric cancer susceptibility. Carcinogenesis (2012) 0.89